Codexis (NASDAQ:CDXS) Posts Earnings Results, Beats Estimates By $0.08 EPS

Codexis (NASDAQ:CDXSGet Rating) released its quarterly earnings data on Thursday. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.08, Briefing.com reports. The firm had revenue of $38.41 million during the quarter, compared to analyst estimates of $37.86 million. Codexis had a negative return on equity of 12.56% and a negative net margin of 16.85%. The business’s quarterly revenue was up 50.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.07) earnings per share. Codexis updated its FY 2022 guidance to EPS.

Codexis Stock Up 9.6 %

Codexis stock traded up $0.77 during midday trading on Friday, reaching $8.75. 1,185,975 shares of the stock traded hands, compared to its average volume of 964,661. The stock’s fifty day moving average is $9.61 and its 200-day moving average is $14.62. Codexis has a 12 month low of $6.15 and a 12 month high of $42.01. The stock has a market cap of $571.41 million, a P/E ratio of -26.52 and a beta of 1.61.

Wall Street Analysts Forecast Growth

CDXS has been the subject of a number of recent analyst reports. Craig Hallum dropped their price objective on Codexis from $42.00 to $19.00 in a research note on Friday, July 15th. HC Wainwright dropped their price objective on Codexis from $38.00 to $27.00 in a research note on Monday, July 18th. Cowen dropped their price objective on Codexis from $39.00 to $21.00 and set an “outperform” rating for the company in a research note on Friday, July 15th. Benchmark set a $20.00 price objective on Codexis in a research note on Tuesday, July 19th. Finally, Piper Sandler dropped their price target on Codexis from $35.00 to $22.00 and set an “overweight” rating for the company in a research note on Thursday, July 14th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $21.67.

Insider Activity at Codexis

In other news, CEO John J. Nicols sold 38,500 shares of the firm’s stock in a transaction that occurred on Thursday, May 12th. The stock was sold at an average price of $10.31, for a total value of $396,935.00. Following the completion of the sale, the chief executive officer now directly owns 1,022,679 shares of the company’s stock, valued at approximately $10,543,820.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Codexis

Several institutional investors have recently modified their holdings of CDXS. Quantbot Technologies LP bought a new stake in shares of Codexis in the 1st quarter valued at approximately $33,000. US Bancorp DE lifted its stake in shares of Codexis by 517.5% in the 1st quarter. US Bancorp DE now owns 8,380 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 7,023 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Codexis by 15.8% in the 2nd quarter. Envestnet Asset Management Inc. now owns 31,812 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 4,352 shares during the last quarter. Bridgewater Associates LP lifted its stake in shares of Codexis by 42.4% in the 1st quarter. Bridgewater Associates LP now owns 19,050 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 5,670 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in shares of Codexis by 14.2% in the 1st quarter. Royal Bank of Canada now owns 21,891 shares of the biotechnology company’s stock valued at $451,000 after purchasing an additional 2,721 shares during the last quarter.

Codexis Company Profile

(Get Rating)

Codexis, Inc discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services.

Recommended Stories

Earnings History for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.